She was subsequently treated with Carboplatin, Paclitaxel and trastuzumab as adjuvant systemic treatment; this regimen was selected given evidence of activity in both malignancies for the chemotherapy component, with the trastuzumab directed towards the Her2-positive early breast cancer (EBC). The gene discussed is ERBB2; the disease is breast cancer.